Prospective Non-randomized Stratified Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib) in Adults With Ph+ Chronic Myeloid Leukemia With Stable Deep Molecular Response
Latest Information Update: 16 Aug 2022
At a glance
- Drugs Bosutinib (Primary) ; Dasatinib (Primary) ; Imatinib (Primary) ; Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms READIT
- 17 Jun 2022 First Interim Results (n=103) presented at the 27th Congress of the European Haematology Association
- 17 Jun 2021 Interim results (n=70; as of Mar 2021) presented at the 26th Congress of the European Haematology Association
- 08 Oct 2020 New trial record